TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03293394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal bilateral motor cortex and cathodal spinal tDCS
Description: 10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham bilateral motor cortex and sham spinal tDCS
Description: 10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study: NCT04557358

Intervention type: OTHER
Intervention: IER-R (posttraumatic stress)
Description: The instrument measures the presence of posttraumatic stress
Study: NCT02721992

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02256839

Intervention type: DEVICE
Intervention: CST_001

Intervention type: DEVICE
Intervention: CST_001
Study: NCT02267070

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and supportive psychotherapy
Description: An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management and supportive psychotherapy
Description: An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family psychoeducation
Description: All immediate family members will be invited to family psychoeducation sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family psychoeducation
Description: All immediate family members will be invited to family psychoeducation sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
Study: NCT01986738

Intervention type: RADIATION
Intervention: Standard Radiation Therapy
Description: Radiotherapy will be planned and delivered according to institutional standard of care.
Study: NCT04480775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: transversus abdominis plane block with bupivacain and triamicinolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: transversus abdominis plane block with bupivacaine and methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: transversus abdominis plane block with bupivacaine alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: transversus abdominis plane block with bupivacaine alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: transversus abdominis plane block with bupivacaine alone
Study: NCT01986738

Intervention type: DEVICE
Intervention: Active Breathing Control Device (ABC)

Intervention type: DEVICE
Intervention: Computed Tomography Scan (CT)
Study: NCT01918917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: intraarticular

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intraarticular 1 ml (100 mcg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intraarticular 1 ml (100 mcg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenously, patient-controlled analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenously, patient-controlled analgesia
Study: NCT01744470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted half-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus targeted plain dose
Study: NCT03042923

Intervention type: DRUG
Intervention: lactulose:mannitol (L:M) oral challenge

Intervention type: DRUG
Intervention: lactulose:mannitol (L:M) oral challenge
Study: NCT02037620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-6-5 Specify electrode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restore Advance Pulse Generator
Study: NCT03979534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low protein diet
Description: Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
Study: NCT01839097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~* Cohort 1: belinostat 1000 mg/m2 IV on Day 1~* Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~* Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~* Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~* Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat.
Study: NCT03253445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
Study: NCT03308175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flat fixed anterior bite plane
Description: It causes unlocking mandible from deep bite in growing females

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified inclined fixed anterior bite plane
Description: It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
Study: NCT02212652

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 10,000 IU of VitD3 daily (one gel daily)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gummy button placebo, which will appear very similar to the vitamin D supplement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
Study: NCT04703205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3 MG
Description: Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
Study: NCT01818531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar plexus block
Study: NCT03664102

Intervention type: DEVICE
Intervention: Cor Knot
Description: Heart valve replacement with or without the use of automated fastener device Cor Knot
Study: NCT05963477

Intervention type: PROCEDURE
Intervention: laparatomy
Description: all abdominal procedures which are approached by different incisions

Intervention type: PROCEDURE
Intervention: laparatomy
Description: all abdominal procedures which are approached by different incisions

Intervention type: PROCEDURE
Intervention: laparatomy
Description: all abdominal procedures which are approached by different incisions

Intervention type: PROCEDURE
Intervention: laparatomy
Description: all abdominal procedures which are approached by different incisions

Intervention type: PROCEDURE
Intervention: laparatomy
Description: all abdominal procedures which are approached by different incisions

Intervention type: PROCEDURE
Intervention: laparatomy
Description: all abdominal procedures which are approached by different incisions
Study: NCT00513877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT01093469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atopiclair Nonsteroidal Cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram
Study: NCT03274895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHMB 0.08%
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propamidine 0.1%
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PHMB 0.02%
Description: 16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
Study: NCT00477490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin acetate
Description: Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin acetate
Description: Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin acetate
Description: Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin acetate
Description: Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
Study: NCT01223547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants are taught the principles of carb counting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
Study: NCT04247477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation strategy
Description: Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation strategy
Description: Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
Study: NCT01646177

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03292185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Study: NCT01646177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg etanercept
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab
Description: Administered SC
Study: NCT01068665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study: NCT01546077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of perineural catheters with Hydrolocalization technique using
Description: Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of perineural catheters with Hydrolocalization technique using
Description: Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
Study: NCT01373580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Raindrop Near Vision Inlay
Description: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
Study: NCT01613482

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: cerebral prophylactic radiation
Description: 24Gy, 12 fractions of 2 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Weekly, 2mg/kg of corporal weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Weekly, 2mg/kg of corporal weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other chemotherapy in association with Trastuzumab
Description: other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other chemotherapy in association with Trastuzumab
Description: other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
Study: NCT02882425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag for intravenous use
Description: Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag for intravenous use
Description: Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
Study: NCT02882425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag for intravenous use
Description: Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag for oral use
Description: Tablet containing 200 µg of selexipag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag for oral use
Description: Tablet containing 200 µg of selexipag
Study: NCT03292185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Study: NCT02199158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Laser Peripheral Iridoplasty
Description: ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
Study: NCT03292185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Study: NCT01584960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endurance training
Description: 2 years of home-based endurance training
Study: NCT03846453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL036 Ophthalmic Solution
Description: HL036 Ophthalmic Solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vehicle solution
Study: NCT02888574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
Study: NCT03292185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh
Study: NCT02888574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study: NCT04210921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi .

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The park sham needle
Description: When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
Study: NCT02378038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNT2258
Study: NCT03271853

Intervention type: DEVICE
Intervention: Sentinel BreastScan II
Description: The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
Study: NCT03697122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Humidified Breathing Circuit and Forced Air Blanket
Description: Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming.